Day Zero Diagnostics Funding Round

9/22/2023

Venture Equity

$16,000,000

Undisclosed

The company intends to use the funds to complete development of an improved Blood2Bac� sample prep protocol, which can capture fungi as well as bacteria, using smaller sample volumes, and at substantially lower cost. The funding will also accelerate development of a prototype for the commercial system, including both the hardware system and the Keynome® family of cloud-based AI algorithms that provides high accuracy organism ID and antimicrobial susceptibility profiling. Using the diagnostic, hospitals will be able to reduce patient length of stay; the overuse of toxic, expensive, and ineffective antibiotics; and most importantly, save lives.

Private & Independent

Healthcare IT

127 Western Ave.
Boston, MA 02134
USA

Day Zero Diagnostics (DZD) is developing a new class of diagnostic that enables a physician to switch from broad spectrum antibiotic therapy to a targeted antibiotic in 5 hours rather than the 2-5 days that it typically takes today.